Key Takeaways
- • Thermo Fisher Scientific divests its microbiology division to Astorg in a $1.08 billion transaction, funded through cash proceeds and a $50 million seller note, representing Astorg VIII's tenth investment to date.
- • The divested microbiology unit generated $645 million in revenues during 2025 and specializes in antimicrobial susceptibility testing and culture media serving clinical diagnostics, pharmaceutical development, and food safety applications.
- • The transaction is expected to close in the second half of 2026 and will reduce Thermo Fisher's adjusted earnings per share by $0.15 in the first full year post-closing, reflecting the divestment's impact on profitability.
- • The sale aligns with CEO Marc Casper's stated strategy of portfolio optimization and capital reallocation toward opportunities that enhance shareholder returns.
Summary
Thermo Fisher Scientific has agreed to sell its microbiology division to Paris-based private equity firm Astorg for approximately $1.08 billion, marking a significant portfolio repositioning by the life sciences company. The transaction, executed through Astorg VIII, represents the fund's tenth investment and will be structured with a combination of cash proceeds and a $50 million seller note, according to the company statement.
The microbiology business operates within Thermo Fisher's specialty diagnostics segment and generated $645 million in annual revenues during 2025. The unit focuses on antimicrobial susceptibility testing and culture media products with applications across three primary markets: clinical diagnostics for infection identification and treatment, pharmaceutical development for drug efficacy assessment, and food safety testing. These capabilities position the business as a specialized player in infection control and safety testing across healthcare and industrial sectors.
CEO Marc Casper characterized the divestment as part of Thermo Fisher's broader portfolio optimization strategy, emphasizing the company's intent to redeploy capital toward higher-return opportunities for shareholders. The transaction is expected to reach completion during the second half of 2026, with Thermo Fisher anticipating a $0.15 reduction in adjusted earnings per share in the first full year following closing. This earnings headwind reflects the revenue contribution and profitability profile of the divested unit relative to company-wide metrics.
The sale demonstrates continued activity among institutional investors in life sciences support services, with Astorg targeting specialized diagnostics and testing capabilities serving regulated markets. The transaction values the microbiology business at a multiple reflecting its steady revenue base and market position in essential testing infrastructure.
The microbiology business operates within Thermo Fisher's specialty diagnostics segment and generated $645 million in annual revenues during 2025. The unit focuses on antimicrobial susceptibility testing and culture media products with applications across three primary markets: clinical diagnostics for infection identification and treatment, pharmaceutical development for drug efficacy assessment, and food safety testing. These capabilities position the business as a specialized player in infection control and safety testing across healthcare and industrial sectors.
CEO Marc Casper characterized the divestment as part of Thermo Fisher's broader portfolio optimization strategy, emphasizing the company's intent to redeploy capital toward higher-return opportunities for shareholders. The transaction is expected to reach completion during the second half of 2026, with Thermo Fisher anticipating a $0.15 reduction in adjusted earnings per share in the first full year following closing. This earnings headwind reflects the revenue contribution and profitability profile of the divested unit relative to company-wide metrics.
The sale demonstrates continued activity among institutional investors in life sciences support services, with Astorg targeting specialized diagnostics and testing capabilities serving regulated markets. The transaction values the microbiology business at a multiple reflecting its steady revenue base and market position in essential testing infrastructure.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.